Advertisement
Advertisement
NAMS
NewAmsterdam Pharma Company N.V. Ordinary Shares
27.96
USDSponsored
+0.29
+1.05%
Aug 07, 15:59 UTC -4
Closed
After-Market
28.14
+0.18
+0.63%
NAMS Earnings Reports
Positive Surprise Ratio
NAMS beat 6 of 11 last estimates.
55%
Next Report
In 3 Days
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
$1.70M
/-$0.49
Implied change from Q1 26 (Revenue/ EPS)
-44.21%
/+22.50%
Implied change from Q2 25 (Revenue/ EPS)
-91.14%
/+226.67%
NewAmsterdam Pharma Company N.V. Ordinary Shares earnings per share and revenue
On May 07, 2026, NAMS reported earnings of -0.40 USD per share (EPS) for Q1 26, beating the estimate of -0.50 USD, resulting in a 20.32% surprise. Revenue reached 3.04 million, compared to an expected 875.50 thousand, with a 247.23% difference. The market reacted with a +12.46% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of -0.49 USD, with revenue projected to reach 1.70 million USD, implying an increase of 22.50% EPS, and decrease of -44.21% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
Guardian Pharmacy Services, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.27
Actual
$0.28
Surprise
+3.76%
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Avita Medical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.25
Surprise
+14.50%
FAQ
What were NewAmsterdam Pharma Company N.V. Ordinary Shares's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, NewAmsterdam Pharma Company N.V. Ordinary Shares reported EPS of -$0.40, beating estimates by 20.32%, and revenue of $3.04M, 247.23% above expectations.
How did the market react to NewAmsterdam Pharma Company N.V. Ordinary Shares's Q1 2026 earnings?
The stock price moved up 12.46%, changed from $30.99 before the earnings release to $34.85 the day after.
When is NewAmsterdam Pharma Company N.V. Ordinary Shares expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for NewAmsterdam Pharma Company N.V. Ordinary Shares's next earnings report?
Based on 10
analysts, NewAmsterdam Pharma Company N.V. Ordinary Shares is expected to report EPS of -$0.49 and revenue of $1.70M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement